ANI Pharmaceuticals Reports Second-Quarter 2026 Results, Raises Cortrophin Gel Guidance and Reaffirms Full-Year Outlook
ANI Pharmaceuticals (Nasdaq: ANIP) reported Q2 2026 net revenues of $266.0 million, up 25.9% year over year. Cortrophin Gel net revenues rose to $117.1 million (+43.5%). GAAP net income available to common shareholders was $24.7 million, and adjusted non-GAAP diluted EPS was $2.21. The company raised Cortrophin Gel guidance to $520-$540 million and reaffirmed full-year 2026 net revenue $1,080-$1,140 million and adjusted EBITDA $285-$300 million.
How this was made
The 30-second read
Why it matters
The key tradable update is the Cortrophin Gel net revenue guidance adjustment to $520-$540 million for full-year 2026, supported by early demand metrics from the expanded sales force. Total company revenue and adjusted EBITDA guidance were reaffirmed.
Market read
Traders can update models around Cortrophin Gel growth and assess whether the guidance adjustment changes expectations for 2026 revenue and EBITDA despite reaffirmed totals.
What to watch
Gross margin declined on both GAAP and non-GAAP basis, and the article attributes it to mix and non-recurrence items, which could temper enthusiasm despite revenue growth.
Background
ANI Pharmaceuticals reported Q2 2026 financial results and discussed business highlights for its Rare Disease portfolio, especially Cortrophin Gel gout expansion.
Ticker impact
ANI reported Q2 2026 results and raised/adjusted Cortrophin Gel net revenue guidance to $520-$540 million for full-year 2026.
Likely positive near-term bias as raised Cortrophin Gel outlook supports revenue and EBITDA expectations.
The article provides specific Q2 performance plus a concrete full-year Cortrophin Gel guidance range and reiterates total company guidance, which can drive earnings-model revisions.
Market effects
Rare disease commercial execution and rare-disease sales-force expansion are highlighted as key drivers, potentially informing sentiment toward similar specialty pharma names.
Primarily US-focused demand expansion (podiatrists and primary care) may influence domestic specialty pharma sentiment.
International shipment timing impacts ILUVIEN, but the guidance update is company-specific and not a broad global read-through.
Counterpoint
Cortrophin Gel guidance is adjusted modestly, while total company guidance is reaffirmed, so upside may be limited if investors expected a larger raise.
Key entities
- companyANI Pharmaceuticals, Inc.
Subject of the earnings release, including Q2 results and 2026 guidance updates for Cortrophin Gel and overall company metrics.
- productCortrophin Gel
Rare disease product whose net revenue guidance was adjusted to $520-$540 million for full-year 2026.
- productILUVIEN
Rare disease product with Q2 net revenue decline attributed to timing of international shipments.
